FDA Approves Teva's WELTRUZA, First Monthly Injectable Schizophrenia Treatment
Translated & summarized from Calcalist by baba
The U.S. FDA has approved Teva Pharmaceuticals' WELTRUZA, a new monthly injectable treatment for adults with schizophrenia. Clinical trials showed WELTRUZA improved symptoms, reduced disease severity, and enhanced social functioning. The drug eliminates the need for post-injection monitoring, addressing a key treatment challenge.
The story in 5 lines · by baba
- The FDA approved Teva's WELTRUZA, a new monthly injectable treatment for schizophrenia.
- WELTRUZA is the first monthly injectable treatment for schizophrenia approved by the FDA.
- Clinical trials showed WELTRUZA improved symptoms and social functioning in patients.
- The treatment is administered as a single subcutaneous injection once a month.
- Dr. Eric Hughes stated the drug eliminates the need for post-injection monitoring.
Teva Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved WELTRUZA, a long-acting injectable medication for adults with schizophrenia. This new treatment is administered as a single subcutaneous injection once a month. Clinical trials for WELTRUZA demonstrated significant improvements in schizophrenia symptoms, a reduction in disease severity, and enhanced personal and social functioning.
Dr. Eric Hughes, Teva's Senior Vice President, Head of Global R&D, and Chief Medical Officer, stated that the approval highlights Teva's patient-focused innovation and its R&D capabilities in delivering meaningful solutions. He added that WELTRUZA combines proven science with innovative formulation, eliminating the need for post-injection monitoring and addressing a significant barrier in treatment for individuals living with schizophrenia.
